• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LUCITANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • LUCITANIB chembl:CHEMBL2220486 Antineoplastic

    Alternate Names:

    E-3810
    AL-3810
    CO-3810
    S-80881
    LUCITANIB
    E-3810 AMINE
    E3810
    pubchem.compound:25031915
    chemidplus:1058137-23-7
    chembl:CHEMBL2220486
    drugbank:11845

    Drug Info:

    (1 More Sources)

    Publications:

    Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.
    Soria et al., 2014, Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors., Ann. Oncol.
  • LUCITANIB   FGFR1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Alpelisib + Lucitanib
    Indication/Tumor Type estrogen-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    27126994 25193991


    Sources:
    JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial

  • LUCITANIB   KDR

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes
    Evidence Type Actionable

    PMIDs:
    25193991


    Sources:
    JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

  • LUCITANIB   FLT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions MyCancerGenomeClinicalTrial

  • LUCITANIB   FLT4

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions MyCancerGenomeClinicalTrial

  • LUCITANIB   FGFR2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LUCITANIB   PIK3CA

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Alpelisib + Lucitanib
    Indication/Tumor Type estrogen-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    27126994


    Sources:
    JAX-CKB

  • JAX-CKB: Lucitanib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.
    Soria et al., 2014, Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors., Ann. Oncol.

  • CIViC: LUCITANIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Soria et al., 2014, Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors., Ann. Oncol.

  • ChemblDrugs: chembl:CHEMBL2220486

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: 1058137-23-7

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2220486

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21